Spectral AI reports Q2 EPS (31c) vs. (16c) last year

Reports Q2 revenue $5.07M, consensus $5.44M. “We are pleased with the results of our second quarter of 2025 especially with our ability to complete our submission of our De Novo application earlier than projected to the US Food and Drug Administration. This FDA submission is a major milestone for Spectral AI (MDAI) and the DeepView System, representing a crucial step toward bringing this innovative diagnostic device to market in the U.S. It provides clinicians with an immediate, data-driven assessment tool designed to assist clinical decision-making and may significantly improve patient outcomes,” stated J. Michael DiMaio, MD, Chairman of the Board at Spectral AI. “I am grateful to our shareholders for their continued support as we reach this important milestone. I am also incredibly proud of our team’s dedication and we remain committed to our mission to bring this technology to the broader healthcare market worldwide.”